These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34439728)

  • 1. Acute Regression in Down Syndrome.
    Handen B; Clare I; Laymon C; Petersen M; Zaman S; O'Bryant S; Minhas D; Tudorascu D; Brown S; Christian B
    Brain Sci; 2021 Aug; 11(8):. PubMed ID: 34439728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome.
    Bejanin A; Iulita MF; Vilaplana E; Carmona-Iragui M; Benejam B; Videla L; Barroeta I; Fernandez S; Altuna M; Pegueroles J; Montal V; Valldeneu S; Giménez S; González-Ortiz S; Muñoz L; Padilla C; Aranha MR; Estellés T; Illán-Gala I; Belbin O; Camacho V; Wilson LR; Annus T; Osorio RS; Videla S; Lehmann S; Holland AJ; Zetterberg H; Blennow K; Alcolea D; Clarimon J; Zaman SH; Blesa R; Lleó A; Fortea J
    JAMA Neurol; 2021 Aug; 78(8):937-947. PubMed ID: 34228042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease.
    Startin CM; Ashton NJ; Hamburg S; Hithersay R; Wiseman FK; Mok KY; Hardy J; Lleó A; Lovestone S; Parnetti L; Zetterberg H; Hye A; ; Strydom A
    Alzheimers Res Ther; 2019 Mar; 11(1):26. PubMed ID: 30902060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase.
    Mengel D; Liu W; Glynn RJ; Selkoe DJ; Strydom A; Lai F; Rosas HD; Torres A; Patsiogiannis V; Skotko B; Walsh DM
    Alzheimers Res Ther; 2020 Mar; 12(1):27. PubMed ID: 32192521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Fortea J; Vilaplana E; Carmona-Iragui M; Benejam B; Videla L; Barroeta I; Fernández S; Altuna M; Pegueroles J; Montal V; Valldeneu S; Giménez S; González-Ortiz S; Muñoz L; Estellés T; Illán-Gala I; Belbin O; Camacho V; Wilson LR; Annus T; Osorio RS; Videla S; Lehmann S; Holland AJ; Alcolea D; Clarimón J; Zaman SH; Blesa R; Lleó A
    Lancet; 2020 Jun; 395(10242):1988-1997. PubMed ID: 32593336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrovascular disease drives Alzheimer plasma biomarker concentrations in adults with Down syndrome.
    Edwards NC; Lao PJ; Alshikho MJ; Ericsson OM; Rizvi B; Petersen ME; O'Bryant S; Flores-Aguilar L; Simoes S; Mapstone M; Tudorascu DL; Janelidze S; Hansson O; Handen BL; Christian BT; Lee JH; Lai F; Rosas HD; Zaman S; Lott IT; Yassa MA; Gutierrez J; Wilcock DM; Head E; Brickman AM
    medRxiv; 2023 Nov; ():. PubMed ID: 38076904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers.
    Janelidze S; Christian BT; Price J; Laymon C; Schupf N; Klunk WE; Lott I; Silverman W; Rosas HD; Zaman S; Mapstone M; Lai F; Ances BM; Handen BL; Hansson O
    JAMA Neurol; 2022 Aug; 79(8):797-807. PubMed ID: 35789365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AT(N) biomarker profiles and Alzheimer's disease symptomology in Down syndrome.
    Hartley SL; Handen B; Tudorascu D; Lee L; Cohen A; Schworer EK; Peven JC; Zammit M; Klunk W; Laymon C; Minhas D; Luo W; Zaman S; Ances B; Preboske G; Christian BT;
    Alzheimers Dement; 2024 Jan; 20(1):366-375. PubMed ID: 37641428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.
    Fagan AM; Henson RL; Li Y; Boerwinkle AH; Xiong C; Bateman RJ; Goate A; Ances BM; Doran E; Christian BT; Lai F; Rosas HD; Schupf N; Krinsky-McHale S; Silverman W; Lee JH; Klunk WE; Handen BL; Allegri RF; Chhatwal JP; Day GS; Graff-Radford NR; Jucker M; Levin J; Martins RN; Masters CL; Mori H; Mummery CJ; Niimi Y; Ringman JM; Salloway S; Schofield PR; Shoji M; Lott IT; ;
    Lancet Neurol; 2021 Aug; 20(8):615-626. PubMed ID: 34302786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study.
    Boerwinkle AH; Gordon BA; Wisch J; Flores S; Henson RL; Butt OH; McKay N; Chen CD; Benzinger TLS; Fagan AM; Handen BL; Christian BT; Head E; Mapstone M; Rafii MS; O'Bryant S; Lai F; Rosas HD; Lee JH; Silverman W; Brickman AM; Chhatwal JP; Cruchaga C; Perrin RJ; Xiong C; Hassenstab J; McDade E; Bateman RJ; Ances BM; ;
    Lancet Neurol; 2023 Jan; 22(1):55-65. PubMed ID: 36517172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome.
    Henson RL; Doran E; Christian BT; Handen BL; Klunk WE; Lai F; Lee JH; Rosas HD; Schupf N; Zaman SH; Lott IT; Fagan AM
    Alzheimers Dement (Amst); 2020; 12(1):e12057. PubMed ID: 32671183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI).
    Rafii MS; Lukic AS; Andrews RD; Brewer J; Rissman RA; Strother SC; Wernick MN; Pennington C; Mobley WC; Ness S; Matthews DC;
    J Alzheimers Dis; 2017; 60(2):439-450. PubMed ID: 28946567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome.
    Zammit MD; Tudorascu DL; Laymon CM; Hartley SL; Zaman SH; Ances BM; Johnson SC; Stone CK; Mathis CA; Klunk WE; Cohen AD; Handen BL; Christian BT
    Neuroimage; 2021 Mar; 228():117728. PubMed ID: 33421595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
    Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obstructive sleep apnea, cerebrovascular disease, and amyloid in older adults with Down syndrome across the Alzheimer's continuum.
    Lao P; Zimmerman ME; Hartley SL; Gutierrez J; Keator D; Igwe KC; Laing KK; Cotton-Samuel D; Sathishkumar M; Moni F; Andrews H; Krinsky-McHale S; Head E; Lee JH; Lai F; Yassa MA; Diana Rosas H; Silverman W; Lott IT; Schupf N; Brickman AM
    Sleep Adv; 2022; 3(1):zpac013. PubMed ID: 35669316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer's Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome.
    Petersen ME; Rafii MS; Zhang F; Hall J; Julovich D; Ances BM; Schupf N; Krinsky-McHale SJ; Mapstone M; Silverman W; Lott I; Klunk W; Head E; Christian B; Foroud T; Lai F; Diana Rosas H; Zaman S; Wang MC; Tycko B; Lee JH; Handen B; Hartley S; Fortea J; O'Bryant S;
    J Alzheimers Dis; 2021; 79(2):671-681. PubMed ID: 33337378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterizing the emergence of amyloid and tau burden in Down syndrome.
    Zammit MD; Betthauser TJ; McVea AK; Laymon CM; Tudorascu DL; Johnson SC; Hartley SL; Converse AK; Minhas DS; Zaman SH; Ances BM; Stone CK; Mathis CA; Cohen AD; Klunk WE; Handen BL; Christian BT;
    Alzheimers Dement; 2024 Jan; 20(1):388-398. PubMed ID: 37641577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer's Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study.
    Hendrix JA; Airey DC; Britton A; Burke AD; Capone GT; Chavez R; Chen J; Chicoine B; Costa ACS; Dage JL; Doran E; Esbensen A; Evans CL; Faber KM; Foroud TM; Hart S; Haugen K; Head E; Hendrix S; Hillerstrom H; Kishnani PS; Krell K; Ledesma DL; Lai F; Lott I; Ochoa-Lubinoff C; Mason J; Nicodemus-Johnson J; Proctor NK; Pulsifer MB; Revta C; Rosas HD; Rosser TC; Santoro S; Schafer K; Scheidemantel T; Schmitt F; Skotko BG; Stasko MR; Talboy A; Torres A; Wilmes K; Woodward J; Zimmer JA; Feldman HH; Mobley W
    J Clin Med; 2021 Apr; 10(9):. PubMed ID: 33924960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue.
    Lemoine L; Ledreux A; Mufson EJ; Perez SE; Simic G; Doran E; Lott I; Carroll S; Bharani K; Thomas S; Gilmore A; Hamlett ED; Nordberg A; Granholm AC
    Mol Neurodegener; 2020 Nov; 15(1):68. PubMed ID: 33222700
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.